Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.48 |
| ▸ | GNG2 | P59768 | 1/20 | 0.48 |
| ▸ | GNB1 | P62873 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266530 | 1.00 | FTO (0.57) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL10005881 | 0.89 | FTO (0.64) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL29362878 | 0.88 | FTO (0.73) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL5270629 | 0.88 | FTO (0.73) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL10145499 | 0.88 | MAPT (0.48) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL31110329 | 0.86 | FTO (0.65) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL2586810 | 0.86 | MAPT (0.64) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL29376609 | 0.86 | MAPT (0.64) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL4173117 | 0.85 | FTO (0.79) | FTOMAPTMEN1KMT2ATDP1 | |
| SCHEMBL29871701 | 0.85 | FTO (0.79) | FTOMAPTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107198-A1 | ANTIBODY BIOMARKER TO DIAGNOSE IDIOPATHIC INFLAMMATORY MYOPATHIES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125675-A1 | DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY | H LEE MOFFITT CANCER CENTER AND RESEARCH INST INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731758-A2 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY | The Methodist Hospital (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12590974-B2 | Methods and compositions for cardiovascular disease detection and management | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4705328-A2 | METHODS AND PLATFORM RELATED TO FLUORESCENT PROTEIN BIOSENSORS | Board of Regents, The University of Texas System (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062756-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | H LEE MOFFITT CANCER CT & RES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12565680-B2 | Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy | THE METHODIST HOSPITAL SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260043086-A1 | PREDICTIVE BIOMARKER IN AVASTIN IN COLON CANCER | H LEE MOFFITT CANCER CT & RES (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4689667-A1 | METHODS OF IDENTIFYING IMMUNOGLOBULIN ASSOCIATED WITH ADVERSE REACTIONS | CSL Behring AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-20260021142-A1 | HYDROGELS HAVING CONTROLLED HYDROLYTIC DEGRADATION | GEORGIA TECH RES INST (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3990011-A1 | A PEPTIDE-BASED SCREENING METHOD TO IDENTIFY NEOANTIGENS FOR USE WITH TUMOR INFILTRATING LYMPHOCYTES | H. Lee Moffitt Cancer Center & Research Institute, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3986461-A1 | METHODS AND COMPOSITION FOR A BINDING MOLECULE TARGETING CANCER CELLS EXPRESSING SSX2 PEPTIDE 41-49 IN HLA-A*0201 CONTEXT | Children's National Medical Center (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3980451-A1 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | Yeda Research and Development Co. Ltd (IL) | 2022-04-13 | — | — | EP | disclosed |
| US-11287427-B2 | Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging | VANDERBILT UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220064697-A1 | AMPLIFICATION METHODS AND SYSTEMS FOR MERFISH AND OTHER APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | US | disclosed |
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220050096-A1 | ANALYTE-SENSITIVE PROBES AND CONTACT LENS FOR DIAGNOSIS OF OCULAR PATHOLOGIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-17 | — | — | US | disclosed |
| WO-2022032129-A1 | SINGLE-CELL LOCUS-SPECIFIC PROFILING OF EPIGENETIC MARKS | YALE UNIVERSITY (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2021263211-A9 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY | Houston Methodist Hospital (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-113994001-A | Imaging-based hybrid CRISPR screening | 哈佛学院院长及董事 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | DSTN, PARN, CTSA | FTO 865/4885MAPT 1922/4885MEN1 1242/4885 |
| US-12590974-B2 | Methods and compositions for cardiovascular disease detection and management | TNNT2, SPTBN1, ATP2A2 | FTO 4589/4885MAPT 1246/4885MEN1 2546/4885 |
| US-20260021142-A1 | HYDROGELS HAVING CONTROLLED HYDROLYTIC DEGRADATION | KDM8, PTMS, USP2 | FTO 462/4885MAPT 3125/4885MEN1 4461/4885 |
| US-12565680-B2 | Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy | KDM2A, KDM1A, KDM3A | FTO 428/4885MAPT 1531/4885MEN1 3376/4885 |
| US-20260125675-A1 | DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY | PDCD1LG2, TRMT1L, TTLL12 | FTO 3621/4885MAPT 1637/4885MEN1 3567/4885 |
| US-20260062756-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | CDK12, CHEK1, AURKB | FTO 4523/4885MAPT 3960/4885MEN1 1530/4885 |
| US-20260043086-A1 | PREDICTIVE BIOMARKER IN AVASTIN IN COLON CANCER | WEE2, PARP2, FLT4 | FTO 4759/4885MAPT 4590/4885MEN1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.